Heart rate increases in liraglutide treated chronic heart failure patients : association with clinical parameters and adverse events
Background. Liraglutide, a glucagon-like peptide-1 agonist, is used for treatment of type 2 diabetes and has beneficial cardiovascular properties. However, treatment increases heart rate (HR) and possibly the risk of cardiovascular events in chronic heart failure (CHF) patients. We investigated potential associations between HR changes and clinical, laboratory and echocardiographic parameters and clinical events in liraglutide treated CHF patients. Methods. This was a sub-study of the LIVE study. CHF patients (N = 241) with a left ventricular ejection fraction ≤45% were randomised to 1.8 mg liraglutide daily or placebo for 24 weeks. Electrocardiograms (N = 117) and readouts from cardiac implanted electronic devices (N = 20) were analysed for HR and arrhythmias. Results. In patients with sinus rhythm (SR), liraglutide increased HR by 8 ± 9 bpm (pulse measurements), 9 ± 9 bpm (ECG measurements) and 9 ± 6 bpm (device readouts) versus placebo (all p<.005). Increases in HR correlated with liraglutide dose (p=.01). HR remained unchanged in patients without SR. Serious cardiac adverse events were not associated with HR changes. Conclusions. During 6 months of treatment, HR increased substantially in CHF patients with SR treated with liraglutide but was not associated with adverse events. The long-term clinical significance of increased HR in liraglutide treated CHF patients needs to be determined.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Scandinavian cardiovascular journal : SCJ - 54(2020), 5 vom: 01. Okt., Seite 294-299 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tougaard, Rasmus Stilling [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.02.2021 Date Revised 03.02.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14017431.2020.1751873 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM308770552 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM308770552 | ||
| 003 | DE-627 | ||
| 005 | 20231225132445.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14017431.2020.1751873 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1029.xml |
| 035 | |a (DE-627)NLM308770552 | ||
| 035 | |a (NLM)32292074 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tougaard, Rasmus Stilling |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Heart rate increases in liraglutide treated chronic heart failure patients |b association with clinical parameters and adverse events |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.02.2021 | ||
| 500 | |a Date Revised 03.02.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background. Liraglutide, a glucagon-like peptide-1 agonist, is used for treatment of type 2 diabetes and has beneficial cardiovascular properties. However, treatment increases heart rate (HR) and possibly the risk of cardiovascular events in chronic heart failure (CHF) patients. We investigated potential associations between HR changes and clinical, laboratory and echocardiographic parameters and clinical events in liraglutide treated CHF patients. Methods. This was a sub-study of the LIVE study. CHF patients (N = 241) with a left ventricular ejection fraction ≤45% were randomised to 1.8 mg liraglutide daily or placebo for 24 weeks. Electrocardiograms (N = 117) and readouts from cardiac implanted electronic devices (N = 20) were analysed for HR and arrhythmias. Results. In patients with sinus rhythm (SR), liraglutide increased HR by 8 ± 9 bpm (pulse measurements), 9 ± 9 bpm (ECG measurements) and 9 ± 6 bpm (device readouts) versus placebo (all p<.005). Increases in HR correlated with liraglutide dose (p=.01). HR remained unchanged in patients without SR. Serious cardiac adverse events were not associated with HR changes. Conclusions. During 6 months of treatment, HR increased substantially in CHF patients with SR treated with liraglutide but was not associated with adverse events. The long-term clinical significance of increased HR in liraglutide treated CHF patients needs to be determined | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Type 2 diabetes | |
| 650 | 4 | |a arrhythmias | |
| 650 | 4 | |a cardiovascular events | |
| 650 | 4 | |a heart failure | |
| 650 | 4 | |a incretin hormones | |
| 650 | 7 | |a GLP1R protein, human |2 NLM | |
| 650 | 7 | |a Glucagon-Like Peptide-1 Receptor |2 NLM | |
| 650 | 7 | |a Incretins |2 NLM | |
| 650 | 7 | |a Liraglutide |2 NLM | |
| 650 | 7 | |a 839I73S42A |2 NLM | |
| 700 | 1 | |a Jorsal, Anders |e verfasserin |4 aut | |
| 700 | 1 | |a Tarnow, Lise |e verfasserin |4 aut | |
| 700 | 1 | |a Hansson, Nils Henrik |e verfasserin |4 aut | |
| 700 | 1 | |a Kistorp, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Schou, Morten |e verfasserin |4 aut | |
| 700 | 1 | |a Nielsen, Roni |e verfasserin |4 aut | |
| 700 | 1 | |a Flyvbjerg, Allan |e verfasserin |4 aut | |
| 700 | 1 | |a Videbaek, Lars |e verfasserin |4 aut | |
| 700 | 1 | |a Mølgaard, Henning |e verfasserin |4 aut | |
| 700 | 1 | |a Nielsen, Jens Cosedis |e verfasserin |4 aut | |
| 700 | 1 | |a Gustafsson, Ida |e verfasserin |4 aut | |
| 700 | 1 | |a Wiggers, Henrik |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Scandinavian cardiovascular journal : SCJ |d 1998 |g 54(2020), 5 vom: 01. Okt., Seite 294-299 |w (DE-627)NLM091266157 |x 1651-2006 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2020 |g number:5 |g day:01 |g month:10 |g pages:294-299 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14017431.2020.1751873 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 2020 |e 5 |b 01 |c 10 |h 294-299 | ||